[1] Verna EC. Management of advanced fibrosis in the context of hepatitis C virus infection. Top Antivir Med, 2017, 25: 7-11.
[2] Yan K, Garcia-Tsao G. Novel prevention strategies for bacterial infections in cirrhosis. Expert Opin Pharmacother, 2016, 17: 689-701.
[3] 王蕾, 鲍中英, 苑晓冬. 预防性抗生素应用对肝硬化并消化道出血患者医院感染的影响. 标记免疫分析与临床, 2015, 22: 617-619.
[4] 中华人民共和国卫生部. 医院感染诊断标准( 试行). 中华医学杂志, 2001, 81: 314-320.
[5] Zapater P, González-Navajas JM, Such J, et al. Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. World J Gastroenterol, 2015, 21: 11493-11501.
[6] 薛伟红, 王友春, 韩宏锋, 等. 肝硬化合并上消化道出血患者医院感染的相关因素分析. 中华医院感染学杂志, 2017, 27: 3204-3207.
[7] 潘素荣, 胡俊红, 张玉梅, 等. 预防性应用抗菌药物对肝硬化消化道出血患者医院感染的影响研究. 中华医院感染学杂志, 2016, 26: 755-757.
[8] 刘莉, 朱文艳, 冯姝, 等. 预防性应用抗生素对肝硬化上消化道出血患者感染的影响. 山东医药, 2015, 55: 52-54.
[9] 肖建兵. 氧氟沙星对肝硬化上消化道出血患者医院感染的预防作用评价. 抗感染药学, 2017, 14: 181-183.
[10] Fiore M, Maraolo AE, Gentile I, et al. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis. World J Hepatol, 2017, 9: 1166-1175. |
